Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai's EpimAb Closes $25 Million A Round for Bi-Specifics

publication date: Apr 25, 2017
EpimAb Biotherapeutics, a Shanghai bispecific antibody company, closed a $25 million Series A round, led by Suzhou's Oriza Seed Capital. Founded in 2015, EpimAb developed its novel FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform, which generates bispecific molecules with antibody-like properties. EpimAb believes its molecules will prove to be more potent, less immunogenic and easier to manufacture than the competition. EpimAb, which is building a pipeline of immuno-oncology candidates, expects to start its first clinical trial in 2018. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here